FOLD

NEUTRALM&A

Amicus Therapeutics, Inc.

2026-03-10

Price

$14.36

-0.07%

Score6.0Priority

Signals5/8 DNA1/13 Act · 0/4 Risk

SentimentNEUTRALScore: 8

Volume0.9xvs 20d avg

Analysis

Amicus Therapeutics (FOLD) is currently trading as a pure merger arbitrage play following the definitive agreement to be acquired by BioMarin for $14.50 per share in cash. The exceptionally low realized volatility of 2.1% and technical signals like QUIET_STORM and PERFECT_STACK perfectly reflect the stock's tight peg to this deal price. On March 3, 2026, Amicus shareholders officially approved the acquisition, removing a massive deal hurdle. Furthermore, despite the CAUTION geopolitical regime, the ultra-tight credit spreads (OAS at 0.85%) provide high conviction that the market is pricing in zero financing or systemic risk to the deal's expected Q2 2026 closure.

Fired Signals

ALPHA MALEQUIET STORMGOLDEN CROSSBOLLINGER SQUEEZEPERFECT STACKSELLER FATIGUE

Key Takeaways

M&A Arbitrage Anchor: FOLD is trading at $14.36, representing a tight ~1% spread to the $14.50 all-cash acquisition price from BioMarin.
Shareholder Approval Cleared: The March 3, 2026, stockholder approval removes a significant hurdle, leaving only regulatory clearances before the expected Q2 2026 close.
Macro Tailwinds for M&A: Despite the CAUTION regime and Iran conflict, calm credit markets (0.85% OAS) signal zero deal-break or financing risk.

← Back to 2026-03-10 View Full FOLD History →Yahoo Finance &nearr;